Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer,...

Sensei Biotherapeutics to Participate in Jefferies Healthcare Conference BOSTON, May 25, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer,...

Sensei Biotherapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights - SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of...